Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 163.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,634 shares of the medical equipment provider’s stock after acquiring an additional 4,117 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Lantheus were worth $410,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Lantheus by 4.4% in the third quarter. Vanguard Group Inc. now owns 7,765,120 shares of the medical equipment provider’s stock valued at $546,121,000 after purchasing an additional 326,396 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Lantheus by 18.1% in the fourth quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock valued at $162,731,000 after purchasing an additional 489,203 shares in the last quarter. State Street Corp grew its position in shares of Lantheus by 0.3% in the second quarter. State Street Corp now owns 2,393,559 shares of the medical equipment provider’s stock valued at $158,047,000 after purchasing an additional 7,307 shares in the last quarter. FMR LLC grew its position in shares of Lantheus by 198.2% in the third quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock valued at $149,110,000 after purchasing an additional 1,426,465 shares in the last quarter. Finally, Reinhart Partners LLC. grew its position in shares of Lantheus by 50.4% in the fourth quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock valued at $84,089,000 after purchasing an additional 454,753 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of analyst reports. Truist Financial restated a “buy” rating and issued a $82.00 price target (up from $80.00) on shares of Lantheus in a research report on Monday, February 26th. TheStreet lowered Lantheus from a “b-” rating to a “c” rating in a research report on Monday, December 18th. B. Riley lowered their price objective on Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a research report on Wednesday, January 10th. JMP Securities reiterated a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research report on Friday, February 23rd. Finally, StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $104.14.

Lantheus Trading Down 0.9 %

LNTH opened at $60.25 on Tuesday. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $100.85. The business has a fifty day simple moving average of $60.25 and a 200-day simple moving average of $63.06. The firm has a market cap of $4.13 billion, a P/E ratio of 12.98 and a beta of 0.54. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The business had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. On average, equities analysts expect that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Company insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.